Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™
Elevai Labs has partnered with Yuva Biosciences to file two innovative patents aimed at enhancing hair and scalp care technology. The first patent addresses the combination of Elevai exosomes and Yuva's Y100 mitochondrial technology, potentially offering superior results. The second patent focuses on the use of lipid bilayer nanoparticles as a delivery system. These developments will be integrated into Elevai's S-Series Root Renewal System™, incorporating PREx™ and Y100 technologies, already endorsed by BosleyMD.
The Y100 technology, developed through Yuva's MitoGPT™ AI platform, is highly regarded for combating age-related hair and scalp issues. Elevai's strategic expansion includes full-scale marketing of the S-Series, anticipating significant interest from hair and scalp care professionals.
Elevai Labs ha stretto una partnership con Yuva Biosciences per presentare due brevetti innovativi volti a migliorare la tecnologia per la cura dei capelli e del cuoio capelluto. Il primo brevetto riguarda la combinazione degli esosomi Elevai e della tecnologia mitocondriale Y100 di Yuva, offrendo potenzialmente risultati superiori. Il secondo brevetto si concentra sull'uso di nanoparticelle a doppio strato lipidico come sistema di consegna. Questi sviluppi saranno integrati nel Sistema di Rinnovo delle Radici S-Series™ di Elevai, incorporando le tecnologie PREx™ e Y100, già approvate da BosleyMD.
La tecnologia Y100, sviluppata attraverso la piattaforma AI MitoGPT™ di Yuva, è molto apprezzata per combattere i problemi di capelli e cuoio capelluto legati all'età. L'espansione strategica di Elevai include il marketing su larga scala della S-Series, prevedendo un significativo interesse da parte dei professionisti della cura dei capelli e del cuoio capelluto.
Elevai Labs se ha asociado con Yuva Biosciences para presentar dos patentes innovadoras dirigidas a mejorar la tecnología de cuidado del cabello y el cuero cabelludo. La primera patente aborda la combinación de exosomas de Elevai y la tecnología mitocondrial Y100 de Yuva, lo que potencialmente ofrece resultados superiores. La segunda patente se enfoca en el uso de nanopartículas de bicapa lipídica como sistema de entrega. Estos desarrollos se integrarán en el Sistema de Renovación de Raíces S-Series™ de Elevai, incorporando las tecnologías PREx™ y Y100, ya respaldadas por BosleyMD.
La tecnología Y100, desarrollada a través de la plataforma de IA MitoGPT™ de Yuva, es muy valorada por combatir problemas de cabello y cuero cabelludo relacionados con la edad. La expansión estratégica de Elevai incluye el marketing a gran escala de la S-Series, anticipando un interés significativo por parte de los profesionales del cuidado del cabello y el cuero cabelludo.
Elevai Labs는 Yuva Biosciences와 협력하여 모발 및 두피 관리 기술을 향상시키기 위한 두 가지 혁신적인 특허를 출원했습니다. 첫 번째 특허는 Elevai의 외소체와 Yuva의 Y100 미토콘드리아 기술의 조합을 다루며, 잠재적으로 더 나은 결과를 제공합니다. 두 번째 특허는 약물 전달 시스템으로서의 지질 이중층 나노입자의 사용에 중점을 둡니다. 이러한 개발은 PREx™ 및 Y100 기술을 통합한 Elevai의 S-Series Root Renewal System™에 통합될 것입니다. 이 시스템은 이미 BosleyMD의 지지를 받고 있습니다.
Yuva의 MitoGPT™ AI 플랫폼을 통해 개발된 Y100 기술은 노화 관련 모발 및 두피 문제를 해결하는 데 높은 평가를 받고 있습니다. Elevai의 전략적 확장은 S-Series의 대규모 마케팅을 포함하며, 두피 및 모발 관리 전문가들로부터 상당한 관심을 예상하고 있습니다.
Elevai Labs s'est associé à Yuva Biosciences pour déposer deux brevets innovants visant à améliorer la technologie de soins capillaires et du cuir chevelu. Le premier brevet concerne la combinaison des exosomes Elevai et de la technologie mitochondriale Y100 de Yuva, offrant potentiellement de meilleurs résultats. Le second brevet met l'accent sur l'utilisation de nanoparticules à double couche lipidique comme système de délivrance. Ces développements seront intégrés dans le S-Series Root Renewal System™ d'Elevai, incorporant les technologies PREx™ et Y100, déjà soutenues par BosleyMD.
La technologie Y100, développée grâce à la plateforme AI MitoGPT™ de Yuva, est très appréciée pour lutter contre les problèmes de cheveux et de cuir chevelu liés à l'âge. L'expansion stratégique d'Elevai comprend le marketing à grande échelle de la S-Series, anticipant un intérêt significatif de la part des professionnels des soins capillaires et du cuir chevelu.
Elevai Labs hat sich mit Yuva Biosciences zusammengetan, um zwei innovative Patente einzureichen, die darauf abzielen, die Technologie zur Pflege von Haaren und Kopfhaut zu verbessern. Das erste Patent befasst sich mit der Kombination von Elevai-Exosomen und Yuva's Y100-Mitochondrientechnologie, die potenziell überlegene Ergebnisse liefert. Das zweite Patent konzentriert sich auf die Verwendung von Lipid-Doppelschicht-Nano-Partikeln als Liefersystem. Diese Entwicklungen werden in Elevais S-Series Root Renewal System™ integriert, das die PREx™ und Y100-Technologien umfasst und bereits von BosleyMD unterstützt wird.
Die Y100-Technologie, die über Yuvas MitoGPT™-KI-Plattform entwickelt wurde, gilt als sehr effektiv bei der Bekämpfung altersbedingter Haar- und Kopfhautprobleme. Elevais strategische Expansion umfasst das großangelegte Marketing der S-Series, wobei ein signifikanter Interessenanstieg von Fachleuten für Haar- und Kopfhautpflege erwartet wird.
- Filing of two innovative patents with Yuva Biosciences.
- Incorporation of highly regarded Y100 technology and PREx™ in new products.
- Endorsement by industry leader BosleyMD, highlighting significant innovation.
- Strategic plans for full-scale marketing of Elevai S-Series Root Renewal System™.
- None.
The filing of two patents by Elevai Labs (NASDAQ: ELAB) in collaboration with Yuva Biosciences represents a significant strategic move in the medical aesthetics sector. This partnership could potentially lead to increased market share and revenue growth for Elevai, particularly in the lucrative hair care market. The integration of Yuva's Y100 technology, already recognized by industry leader BosleyMD®, suggests strong commercial viability. However, investors should note that patent filings don't guarantee market success and the timeline for revenue generation from these innovations remains uncertain. The planned marketing of the Elevai S-Series Root Renewal System™ could be a near-term catalyst for the stock, but its impact on financials is yet to be determined.
The combination of Elevai's PREx™ exosome technology with Yuva's Y100 mitochondrial innovation represents a potentially groundbreaking approach in hair and scalp care. The synergistic effect claimed in the patents could offer superior efficacy compared to existing treatments. The use of AI in developing Y100 technology (
The hair care market, particularly for hair loss solutions, represents a significant opportunity for Elevai Labs. With BosleyMD® describing Y100 as "one of the biggest innovations in hair loss we've seen in twenty-five years," there's potential for strong market reception. The Elevai S-Series Root Renewal System™ could capture a substantial market share if it delivers on its promises. However, the competitive landscape in hair care is intense, with numerous established players. Elevai's success will depend on effective marketing, competitive pricing and demonstrable results. The company's ability to differentiate its product in a crowded market and gain consumer trust will be important for long-term success and potential market disruption.
- “One of the Biggest Innovations in Hair Loss We’ve Seen in Twenty-Five Years” - BosleyMD® Teams With Start-up Yuva Biosciences in National Launch of Breakthrough Technology1
- Elevai Labs and Yuva Biosciences Join Forces for Breakthrough in Hair and Scalp Care Technology
NEWPORT BEACH, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics announces the filing of two innovative patents in collaboration with Yuva Biosciences. These patents support the development of Elevai’s innovative solutions for hair and scalp vitality. The first patent, “COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN, SCALP, AND HAIR IMPROVEMENT”, Patent Application Serial No 63/664,517, covers the unique and novel combination of Elevai exosomes and Y100, technologies that the inventors believe are synergistic and could allow significantly better results than either technology used alone. The second patent, “PREPARATIONS INCLUDING LIPID BILAYER NANOPARTICLES”, Patent Application Serial No 63/664,526, covers the use of exosomes (and similar lipid bilayer based nanovesicles) as a unique delivery system while also serving to protect and preserve the molecules being delivered.
Elevai Labs’ recently announced Elevai S-Series Root Renewal System™, is an advanced three-part hair and scalp care regimen. This system incorporates Elevai's proprietary PREx™ (“Precision Regenerative Exosome Technology”) and Yuva Biosciences’ Y100 mitochondrial technology. The Y100 technology, already recognized and utilized by industry leader BosleyMD® in their national launch of Revive Plus Densifying Foam, plays an important role in addressing common scalp and hair concerns such as thinning hair by promoting vitality and reversing signs of aging at the cellular level.
Yuva Biosciences identified the Y100 mitochondrial technology leveraging an advanced AI platform, “MitoGPT™ co-developed by their Chief Scientific Officer, Dr. Keshav K. Singh, and their leading AI team. This innovative technology, based on Dr. Singh’s pioneering research, has already been recognized as a valuable advancement in the fight against age-related hair and skin deterioration. Yuva Biosciences CEO Greg Schmergel commented, “We are excited to have been able to partner with a scientific innovator such as Elevai Labs to successfully combine our award winning technologies to create revolutionary new products for the world of medical aesthetics. We look forward to helping people concerned about the signs of aging through use of the Elevai S-Series Root Renewal System.”
BosleyMD® has lauded the Y100 technology as “one of the biggest innovations in hair loss we’ve seen in twenty-five years,” marking its first successful application in their new product line. Elevai Labs’ integration of this technology into the Elevai S-Series Root Renewal System™ is expected to set a new standard in hair care, offering a scientifically validated, easy-to-use, and cost-effective solution for both men and women.
Elevai’s Strategic Vision for the Future
Elevai Labs is poised to expand the application of their proprietary technologies beyond their current uses. This upcoming product line was recently announced as part of a conference presentation to medical aesthetics professionals by the inventors and scientific co-founders of Elevai Labs and Yuva Biosciences at The Aesthetic Show in Las Vegas, Jordan R. Plews, PhD and Keshav K. Singh, PhD, and the company plans to initiate full-scale marketing of the Elevai S-Series Root Renewal System™ in the near future. Given the demonstrated effectiveness of the underlying technologies, the S-Series is expected to attract keen interest from professional providers in the hair and scalp care market.
About Elevai Labs Inc.
Elevai Labs Inc. (NASDAQ: ELAB) specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics and treatments tied to obesity and metabolic health. The Company operates a diverse portfolio of three wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors, Elevai Skincare Inc., Elevai Biosciences Inc., and Elevai Research Inc. For more information please visit www.elevailabs.com.
About Elevai Skincare Inc.
Elevai Skincare Inc., a subsidiary of Elevai Labs Inc., is a medical aesthetics company developing and commercializing cutting-edge physician-dispensed skin and hair care applications. Elevai Skincare Inc. develops cosmetic products for the physician-dispensed market, with a focus on leveraging novel proprietary science-backed technologies, including its stem cell exosome technology. For more information, please visit www.elevaiskincare.com.
About Yuva Biosciences
Yuva Biosciences is an anti-aging company harnessing the cutting edge of mitochondrial science to develop cosmeceuticals as well as pharmaceuticals targeted at aging-related hair loss, wrinkled skin, and multiple other aging-related conditions. The Company’s Scientific Founder and Chief Scientific Advisor, Keshav K. Singh, Ph.D., is a world leader in the field of mitochondrial biology and genetics and its role in health, disease, and aging. Dr. Singh is the Joy and Bill Harbert Endowed Chair and Professor of Genetics, Pathology and Dermatology at the University of Alabama at Birmingham, and the founding editor-in- chief of the Mitochondrion journal published by Elsevier. Yuva Biosciences is headquartered in Birmingham, Alabama. For more information visit www.yuvabio.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. These risks and uncertainties include, among others: Elevai’s limited operating history and historical losses; Elevai’s ability to raise additional funding to complete the development and any commercialization of its product candidates; Elevai’s dependence on the success of its product candidates EL-22 and EL-32; that Elevai may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Elevai’s ability to obtain, maintain and protect its intellectual property; Elevai’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies; and Elevai’s expectations regarding its growth, strategy, progress and the design, objectives and timing of its studies.
These and other risks are described more fully in Elevai Labs’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact: Makenzie Mann
Email: Contact@Elevailabs.com
1 “One of the Biggest Innovations in Hair Loss We’ve Seen in Twenty-Five Years” -- BosleyMD® Teams With Start-up Yuva Biosciences in National Launch of Breakthrough Technology | Business Wire
FAQ
What new patents has Elevai Labs filed with Yuva Biosciences?
What technology is integrated into Elevai's S-Series Root Renewal System™?
How is BosleyMD involved with Elevai Labs' new technology?
What is the expected market impact of Elevai's new hair and scalp care technology?
